CN115317456A - Nicorandil tablet composition and preparation method thereof - Google Patents

Nicorandil tablet composition and preparation method thereof Download PDF

Info

Publication number
CN115317456A
CN115317456A CN202210987766.8A CN202210987766A CN115317456A CN 115317456 A CN115317456 A CN 115317456A CN 202210987766 A CN202210987766 A CN 202210987766A CN 115317456 A CN115317456 A CN 115317456A
Authority
CN
China
Prior art keywords
nicorandil
tablet composition
granules
vegetable oil
hydrogenated vegetable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210987766.8A
Other languages
Chinese (zh)
Inventor
车楠楠
荣金楼
田素光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Keyuan Chuangxin Technology Co ltd
Original Assignee
Beijing Keyuan Chuangxin Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Keyuan Chuangxin Technology Co ltd filed Critical Beijing Keyuan Chuangxin Technology Co ltd
Priority to CN202210987766.8A priority Critical patent/CN115317456A/en
Publication of CN115317456A publication Critical patent/CN115317456A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention discloses a nicorandil tablet composition and a preparation method thereof, wherein the nicorandil tablet composition comprises the following components: the nicorandil-containing sodium sulfate-containing emulsion comprises nicorandil, carboxymethyl cellulose alkali metal salt, lactose, sodium dodecyl sulfate and hydrogenated vegetable oil, and the sample preparation is carried out by a wet granulation process, so that the stability of a product can be remarkably improved; because the pharmaceutical composition can achieve satisfactory stability by adopting a conventional packaging form, and avoids the use of a special packaging form and packaging equipment, the invention can greatly reduce the commercial production cost while remarkably improving the commercial production efficiency of the nicorandil tablet, and has great social benefit and market value.

Description

Nicorandil tablet composition and preparation method thereof
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a nicorandil tablet composition and a preparation method thereof.
Background
Nicorandil (Nicorandil) has the chemical name of N- (2-hydroxyethyl) nicotinamide nitrate, the CAS number of 65141-46-0, the molecular formula of C8H9N3O4, the molecular weight of 211.18 and the structural formula as follows:
Figure BDA0003802501120000011
nicorandil nitrate compounds have the effects of preventing calcium ions in cells from dissociating, increasing the permeability of cell membranes to potassium ions, expanding coronary vessels, continuously increasing coronary artery blood flow and inhibiting coronary artery spasm, and do not influence blood pressure, heart rate, myocardial contractility and myocardial oxygen consumption when expanding the coronary vessels. At the same time, it also has the action of inhibiting platelet aggregation and preventing thrombosis. Clinically, nicorandil preparation comprises tablets and injections, is mainly suitable for treating coronary heart disease and angina, and can be used for treating labor type, spontaneous type, post-infarction or mixed angina and angina accompanied with atrial fibrillation and cardiac dilatation.
As described in different patents (EP 1001773, US4822808, WO 2006016040), the stability of pharmaceutical compositions of nicorandil in solid form is generally unsatisfactory, in particular under acid, high temperature, high humidity, light and oxygen conditions. Therefore, special precautions are required during the preparation and storage of the nicorandil-containing solid products in order to inhibit or retard degradation processes which may lead to degradation of the active ingredient. Currently, commercial products are generally packaged in special ways to improve the stability of nicorandil tablets, such as uk products (trade name:
Figure BDA0003802501120000021
) While adopting aluminum-aluminum blister package, one of the aluminum-aluminum blister packagesThe blister is filled with a silica gel desiccant and is in communication with other blisters to reduce the effect of moisture on product stability, while products marketed in japan and china (trade name in english:
Figure BDA0003802501120000022
trade name of Chinese:
Figure BDA0003802501120000023
) The aluminum-plastic blister and the moisture-proof bag are adopted for packaging, and a drying agent is added between two packaging materials. The packaging forms of the two products are complicated, and are not beneficial to commercial production.
Chinese patent CN 85109190A discloses a method for preparing stable pharmaceutical preparation containing nicorandil, wherein the pharmaceutical preparation comprises nicorandil, sugar (such as oligosaccharide like lactose, sucrose, maltose) and organic acid (such as dibasic acid like fumaric acid, oxalic acid, salicylic acid), but this patent technology has two defects: firstly, the particle size of the adopted oligosaccharide needs to be controlled below 10 mu m, and secondly, a drying agent needs to be additionally added to improve the stability of the nicorandil preparation, so that the commercial production efficiency of the nicorandil preparation is reduced and the production cost is improved.
Chinese patent CN 100591356C discloses a pharmaceutical composition containing nicorandil and its preparation method, the pharmaceutical composition comprises nicorandil, higher saturated fatty acid and its salt and/or higher alcohol (such as palmitic acid, stearic acid, cetyl alcohol, stearyl alcohol, etc.), croscarmellose sodium as disintegrant and mannitol as diluent, which are used as lubricant and are not micronized, and are solid at ambient temperature, and its preparation method is that the powder is directly tableted. The patent technology has the advantages of simple production process and commercial production, but the stability of the product is not obviously improved compared with the existing commercial product, and the problem of poor product stability cannot be solved.
Chinese patent CN 1839836A discloses a preparation method of nicorandil tablet, which comprises direct powder tabletting, dry granulation tabletting and blank granule method. The product prepared according to this patented technology was left for 4 weeks under accelerated conditions (40 ℃/75% RH), the content was reduced by about 15%, and the problem of poor product stability was not solved yet.
In conclusion, in order to simplify the commercial production packaging form and delay the degradation of the product in the storage process, the problem of how to improve the stability of the nicorandil solid preparation, particularly the tablet, is still urgently needed to be solved.
Disclosure of Invention
The invention aims to provide a nicorandil tablet composition and a preparation method thereof, and solves the problems in the background technology.
The invention is realized in such a way that a nicorandil tablet composition comprises the following components: .
The further technical scheme of the invention is as follows: the nicorandil tablet composition comprises the following components: the nicorandil-containing emulsion comprises nicorandil, carboxymethyl cellulose alkali metal salt, lactose, sodium dodecyl sulfate and hydrogenated vegetable oil, wherein the nicorandil, the carboxymethyl cellulose alkali metal salt, the lactose, the sodium dodecyl sulfate and the hydrogenated vegetable oil comprise the following components in percentage by weight: 2.5 to 7.5 percent of nicorandil, 2.5 to 7.5 percent of carboxymethyl cellulose alkali metal salt, 67 to 83 percent of lactose, 6 to 9 percent of hydrogenated vegetable oil and 6 to 9 percent of lauryl sodium sulfate.
The further technical scheme of the invention is as follows: the carboxymethyl cellulose alkali metal salt is: sodium carboxymethyl cellulose or calcium carboxymethyl cellulose.
The invention further adopts the technical scheme that: the carboxymethyl cellulose alkali metal salt is: calcium carboxymethylcellulose
The further technical scheme of the invention is as follows: the weight percentage of the hydrogenated vegetable oil is 8%.
The invention further adopts the technical scheme that: the weight percentage of the sodium dodecyl sulfate is 8%.
The further technical scheme of the invention is as follows: the weight ratio of the hydrogenated vegetable oil to the sodium dodecyl sulfate is 1.
The invention is realized in such a way that a preparation method of the nicorandil tablet composition comprises the following steps:
step 1: dissolving hydrogenated vegetable oil in cyclohexane under stirring to obtain solution;
and 2, step: mixing nicorandil, lactose and carboxymethyl cellulose alkali metal salt uniformly in a wet granulator, adding ethanol solution, stirring to obtain soft material, and grading to obtain wet granules;
and step 3: putting the wet granules obtained in the step (2) into a multifunctional fluidized bed, setting the temperature to be 40-60 ℃, drying until the moisture of the granules is not higher than 0.5%, and finishing the granules to obtain dry granules;
and 4, step 4: putting the dry particles obtained in the step (3) into a multifunctional fluidized bed, setting the temperature to be 30-50 ℃, atomizing and adding the hydrogenated vegetable oil solution obtained in the step (1), and drying until the residual quantity of cyclohexane is not higher than 50ppm after the liquid is added to obtain dry particles;
and 5: taking the dry particles obtained in the step (4) and sodium dodecyl sulfate, and uniformly mixing the dry particles and the sodium dodecyl sulfate in a three-dimensional mixer to obtain an intermediate;
step 6: taking the intermediate obtained in the step 5, and tabletting by adopting a rotary tablet press to obtain nicorandil tablets;
and 7: and (5) taking the nicorandil tablets obtained in the step (6), and packaging by adopting an aluminum-aluminum bubble cap.
The invention further adopts the technical scheme that: the concentration of the ethanol solution in the step 2 is 85-95%.
The further technical scheme of the invention is as follows: drying the wet granules in the step 3 until the moisture of the granules is not higher than 0.2 percent
The invention has the beneficial effects that: the nicorandil tablet prepared by the invention can ensure the stability of the nicorandil tablet and delay the degradation speed of active ingredients in the storage process by adopting conventional aluminum-aluminum blister packaging. Therefore, the technology of the invention can effectively ensure the product quality while reducing the production cost and improving the production efficiency, provides guarantee for safe and effective medication in clinic and has good social benefit and market value.
Drawings
FIG. 1 is a comparative graph of the stability test provided by the present invention.
Detailed Description
The first embodiment is as follows:
prescription:
Figure BDA0003802501120000051
the preparation method comprises the following steps:
placing hydrogenated vegetable oil in 60g of cyclohexane, and stirring for dissolving to obtain a solution for later use; mixing nicorandil, lactose and sodium carboxymethylcellulose uniformly in a wet granulator, adding 85% ethanol solution, stirring to obtain soft material, and grading; placing the obtained wet granules in a multifunctional fluidized bed, setting the temperature to be 40 ℃, drying until the water content of the granules is 0.5% or below, carrying out granulation, placing the obtained dry granules in the multifunctional fluidized bed, setting the temperature to be 30 ℃, adding the hydrogenated vegetable oil cyclohexane solution in an atomizing manner, after the liquid adding is finished, drying until the cyclohexane residual quantity is 50ppm or below, taking out the dry granules, adding sodium dodecyl sulfate, placing in a three-dimensional mixer, mixing uniformly, tabletting, and carrying out aluminum-aluminum bubble cap packaging to obtain the product.
Example 2
Prescription:
Figure BDA0003802501120000052
the preparation method comprises the following steps:
putting hydrogenated vegetable oil into 90g of cyclohexane, and stirring and dissolving to obtain a solution for later use; mixing nicorandil, lactose and sodium carboxymethylcellulose uniformly in a wet granulator, adding 95% ethanol solution, stirring to obtain soft material, and grading; placing the obtained wet granules in a multifunctional fluidized bed, setting the temperature to be 60 ℃, drying until the water content of the granules is 0.2% or below, carrying out granulation, placing the obtained dry granules in the multifunctional fluidized bed, setting the temperature to be 50 ℃, adding the hydrogenated vegetable oil cyclohexane solution in an atomized manner, after the liquid adding is finished, drying until the cyclohexane residual quantity is 50ppm or below, taking out the dry granules, adding sodium dodecyl sulfate, placing in a three-dimensional mixer, mixing uniformly, tabletting, and carrying out aluminum-aluminum blister packaging to obtain the product.
Example 3
Prescription:
Figure BDA0003802501120000061
the preparation method comprises the following steps:
putting hydrogenated vegetable oil into 80g of cyclohexane, and stirring and dissolving to obtain a solution for later use; mixing nicorandil, lactose and sodium carboxymethylcellulose uniformly in a wet granulator, adding 90% ethanol solution, stirring to obtain soft material, and grading; placing the obtained wet granules in a multifunctional fluidized bed, setting the temperature to be 50 ℃, drying until the water content of the granules is 0.2% or below, carrying out granulation, placing the obtained dry granules in the multifunctional fluidized bed, setting the temperature to be 40 ℃, adding the hydrogenated vegetable oil cyclohexane solution in an atomizing manner, after the liquid adding is finished, drying until the cyclohexane residual quantity is 50ppm or below, taking out the dry granules, adding sodium dodecyl sulfate, placing in a three-dimensional mixer, mixing uniformly, tabletting, and carrying out aluminum-aluminum bubble cap packaging to obtain the product.
Example 4
Prescription:
Figure BDA0003802501120000071
the preparation method comprises the following steps:
putting hydrogenated vegetable oil in 90g of cyclohexane, and stirring for dissolving to obtain a solution for later use; mixing nicorandil, lactose and sodium carboxymethylcellulose uniformly in a wet granulator, adding 95% ethanol solution, stirring to obtain soft material, and grading; placing the obtained wet granules in a multifunctional fluidized bed, setting the temperature to be 50 ℃, drying until the water content of the granules is 0.2% or below, carrying out granulation, placing the obtained dry granules in the multifunctional fluidized bed, setting the temperature to be 40 ℃, adding the hydrogenated vegetable oil cyclohexane solution in an atomized manner, after the liquid adding is finished, drying until the cyclohexane residual quantity is 50ppm or below, taking out the dry granules, adding sodium dodecyl sulfate, placing in a three-dimensional mixer, mixing uniformly, tabletting, and carrying out aluminum-aluminum blister packaging to obtain the product.
Example 5
Prescription:
Figure BDA0003802501120000072
Figure BDA0003802501120000081
the preparation method comprises the following steps:
placing hydrogenated vegetable oil in 60g of cyclohexane, and stirring and dissolving to obtain a solution for later use; mixing nicorandil, lactose and sodium carboxymethylcellulose uniformly in a wet granulator, adding 90% ethanol solution, stirring to obtain soft material, and grading; placing the obtained wet granules in a multifunctional fluidized bed, setting the temperature to be 50 ℃, drying until the water content of the granules is 0.2% or below, granulating, placing the obtained dry granules in the multifunctional fluidized bed, setting the temperature to be 40 ℃, adding the hydrogenated vegetable oil cyclohexane solution in an atomizing manner, drying until the cyclohexane residual quantity is 50ppm or below after liquid adding is finished, taking out the dry granules, adding sodium dodecyl sulfate, placing in a three-dimensional mixer, uniformly mixing, tabletting, and packaging with aluminum-aluminum bubble caps to obtain the product.
Comparative example 1
Prescription:
Figure BDA0003802501120000082
the preparation method comprises the following steps:
mixing nicorandil, lactose and sodium carboxymethylcellulose uniformly in a wet granulator, adding 90% ethanol solution, stirring to obtain soft material, and grading; placing the obtained wet granules in a multifunctional fluidized bed, setting the temperature at 50 deg.C, drying until the water content of the granules is 0.2% or below, grading, adding sodium dodecyl sulfate into the obtained dry granules, mixing in a three-dimensional mixer, tabletting, and packaging with aluminum-aluminum bubble cap.
Comparative example 2
Prescription:
Figure BDA0003802501120000091
the preparation method comprises the following steps:
placing hydrogenated vegetable oil in 80g of cyclohexane, and stirring for dissolving to obtain a solution for later use; mixing nicorandil, lactose and sodium carboxymethylcellulose uniformly in a wet granulator, adding 90% ethanol solution, stirring to obtain soft material, and grading; placing the obtained wet granules in a multifunctional fluidized bed, setting the temperature to be 50 ℃, drying until the water content of the granules is 0.2% or below, carrying out granulation, placing the obtained dry granules in the multifunctional fluidized bed, setting the temperature to be 40 ℃, adding the hydrogenated vegetable oil cyclohexane solution in an atomized manner, drying until the cyclohexane residue is 50ppm or below after the liquid adding is finished, taking the dry granules, carrying out tabletting, and carrying out aluminum-aluminum blister packaging to obtain the product.
Comparative example 3
Prescription:
Figure BDA0003802501120000092
the preparation method comprises the following steps:
mixing nicorandil, mannitol and polyvidone K30 uniformly in a wet granulator, adding 85% ethanol solution, stirring to obtain soft material, and grading; placing the obtained wet granules in a multifunctional fluidized bed, setting the temperature at 50 deg.C, drying until the water content of granules is 0.5% or below, grading, adding stearyl alcohol into the dry granules, mixing in a three-dimensional mixer, tabletting, and packaging with aluminum-aluminum blister.
Comparison of stability
Taking the above example sample, comparative example sample and commercial product
Figure BDA0003802501120000101
And commercially available products
Figure BDA0003802501120000102
Respectively subjected to accelerated test (40 deg.C)RH content: 75) for 6 months, and the content was measured at 0, 3 and 6 months, respectively, as follows:
Figure BDA0003802501120000103
from the above stability test results, it can be seen that the samples prepared by the method of the present invention have significantly better stability than the comparative examples and commercial products under accelerated test (40 ℃/75% RH), as detailed in FIG. 1. Therefore, the method effectively solves the stability problem of the nicorandil tablet, realizes the possibility of adopting a conventional packaging form in the commercial production process, can greatly improve the production efficiency and reduce the production cost, and ensures the safety and the effectiveness of clinical medication.
The above description is intended to be illustrative of the preferred embodiment of the present invention and should not be taken as limiting the invention, but rather, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.

Claims (9)

1. A nicorandil tablet composition is characterized in that: the nicorandil tablet composition comprises the following components: the Nicorandil, carboxymethyl cellulose alkali metal salt, lactose, sodium dodecyl sulfate and hydrogenated vegetable oil comprise the following components in percentage by weight: 2.5 to 7.5 percent of nicorandil, 2.5 to 7.5 percent of carboxymethyl cellulose alkali metal salt, 67 to 83 percent of lactose, 6 to 9 percent of hydrogenated vegetable oil and 6 to 9 percent of lauryl sodium sulfate.
2. The nicorandil tablet composition according to claim 1, wherein the alkali metal salt of carboxymethyl cellulose is: sodium carboxymethyl cellulose or calcium carboxymethyl cellulose.
3. The nicorandil tablet composition according to claim 2, wherein the carboxymethyl cellulose alkali metal salt is: calcium carboxymethylcellulose.
4. The nicorandil tablet composition of claim 1, wherein the hydrogenated vegetable oil is used in an amount of 8% by weight.
5. The nicorandil tablet composition according to claim 1, wherein the sodium lauryl sulfate is used in an amount of 8% by weight.
6. The preparation method of the nicorandil tablet composition as claimed in claim 1, wherein the weight ratio of the hydrogenated vegetable oil to the sodium dodecyl sulfate is 1.
7. A process for the preparation of a nicorandil tablet composition according to any one of claims 1 to 6, wherein the nicorandil tablet composition is prepared by the steps of:
step 1: dissolving hydrogenated vegetable oil in cyclohexane under stirring to obtain solution;
and 2, step: mixing nicorandil, lactose and carboxymethyl cellulose alkali metal salt uniformly in a wet granulator, adding ethanol solution, stirring to prepare soft materials, and granulating to obtain wet granules;
and step 3: putting the wet granules obtained in the step (2) into a multifunctional fluidized bed, setting the temperature to be 40-60 ℃, drying until the moisture of the granules is not higher than 0.5%, and finishing the granules to obtain dry granules;
and 4, step 4: putting the dry particles obtained in the step (3) into a multifunctional fluidized bed, setting the temperature to be 30-50 ℃, atomizing and adding the hydrogenated vegetable oil solution obtained in the step (1), and drying until the residual quantity of cyclohexane is not higher than 50ppm after the liquid is added to obtain dry particles;
and 5: taking the dry particles obtained in the step (4) and sodium dodecyl sulfate, and uniformly mixing the dry particles and the sodium dodecyl sulfate in a three-dimensional mixer to obtain an intermediate;
step 6: taking the intermediate obtained in the step 5, and tabletting by adopting a rotary tablet press to obtain nicorandil tablets;
and 7: and (4) taking the nicorandil tablets obtained in the step (6), and packaging by adopting an aluminum-aluminum bubble cap to obtain the nicorandil tablet.
8. The preparation method of the nicorandil tablet composition according to claim 7, wherein the concentration of the ethanol solution in the step 2 is 85-95%.
9. The method for preparing a nicorandil tablet composition according to claim 8, wherein the wet granules in the step 3 are dried until the moisture content of the granules is not higher than 0.2%.
CN202210987766.8A 2022-08-17 2022-08-17 Nicorandil tablet composition and preparation method thereof Pending CN115317456A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210987766.8A CN115317456A (en) 2022-08-17 2022-08-17 Nicorandil tablet composition and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210987766.8A CN115317456A (en) 2022-08-17 2022-08-17 Nicorandil tablet composition and preparation method thereof

Publications (1)

Publication Number Publication Date
CN115317456A true CN115317456A (en) 2022-11-11

Family

ID=83924467

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210987766.8A Pending CN115317456A (en) 2022-08-17 2022-08-17 Nicorandil tablet composition and preparation method thereof

Country Status (1)

Country Link
CN (1) CN115317456A (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN85109190A (en) * 1984-12-17 1986-07-16 中外制药株式会社 Produce the method for stable nicorandil preparation
CN87100285A (en) * 1986-01-17 1987-08-19 中外制药株式会社 Produce the method for stable nicorandil preparation
WO1999007370A1 (en) * 1997-08-08 1999-02-18 Biomedica Foscama Industria Chimico-Farmaceutica S.P.A. Oral solid pharmaceutical compositions containing nicorandil for a modulated release and the process for their preparation
CN1839836A (en) * 2006-02-09 2006-10-04 西安力邦医药科技有限责任公司 Method for preparing nicorandil tablet
US20100166857A1 (en) * 2008-12-30 2010-07-01 Dong Yan Pharmaceutical dosage forms and methods of manufacturing same
CN105362243A (en) * 2015-12-18 2016-03-02 重庆福安药业(集团)股份有限公司 Clopidogrel hydrogen sulfate oral administration solid medicine composition and preparation method thereof
CN109406706A (en) * 2018-11-29 2019-03-01 北京市药品检验所 Method of the nicorandil tablet in relation to substance is measured using HPLC corrector factor method
CN113116834A (en) * 2017-02-15 2021-07-16 江苏威凯尔医药科技有限公司 Quick-release medicinal preparation of anticoagulant and preparation method thereof
CN113633708A (en) * 2021-09-27 2021-11-12 重庆希尔安药业有限公司 Preparation method of stable bruise treating qili composition tablet

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN85109190A (en) * 1984-12-17 1986-07-16 中外制药株式会社 Produce the method for stable nicorandil preparation
CN87100285A (en) * 1986-01-17 1987-08-19 中外制药株式会社 Produce the method for stable nicorandil preparation
WO1999007370A1 (en) * 1997-08-08 1999-02-18 Biomedica Foscama Industria Chimico-Farmaceutica S.P.A. Oral solid pharmaceutical compositions containing nicorandil for a modulated release and the process for their preparation
CN1839836A (en) * 2006-02-09 2006-10-04 西安力邦医药科技有限责任公司 Method for preparing nicorandil tablet
US20100166857A1 (en) * 2008-12-30 2010-07-01 Dong Yan Pharmaceutical dosage forms and methods of manufacturing same
CN105362243A (en) * 2015-12-18 2016-03-02 重庆福安药业(集团)股份有限公司 Clopidogrel hydrogen sulfate oral administration solid medicine composition and preparation method thereof
CN113116834A (en) * 2017-02-15 2021-07-16 江苏威凯尔医药科技有限公司 Quick-release medicinal preparation of anticoagulant and preparation method thereof
CN109406706A (en) * 2018-11-29 2019-03-01 北京市药品检验所 Method of the nicorandil tablet in relation to substance is measured using HPLC corrector factor method
CN113633708A (en) * 2021-09-27 2021-11-12 重庆希尔安药业有限公司 Preparation method of stable bruise treating qili composition tablet

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
傅超美等: "《中药药剂学：汉英对照》", 31 October 2002, 第二军医大学出版社, pages: 347 - 348 *
洪怡等: "《药物制剂新技术与产品开发》", 30 November 2020, 华中科技大学出版社, pages: 33 - 36 *

Similar Documents

Publication Publication Date Title
DK167171B1 (en) PROCEDURE FOR PREPARING A STABLE NICORANDY-CONTAINING PHARMACEUTICAL PREPARATION
US3082154A (en) Improved free-flowing coated antimalarial salts in particulate form
CA1110972A (en) Tableting of microcapsules
FI87043C (en) FOERFARANDE FOER FRAMSTAELLNING AV ETT STABILT PHARMACEUTICAL PREPARATION SOM INNEHAOLLER NIKORANDIL
US11298331B2 (en) Solid pharmaceutical preparation containing levothyroxine
BRPI0305559B1 (en) A process for preparing medicaments in the form of a coated tablet comprising vardenafil hydrochloride trihydrate.
CN103083319A (en) Preparation process of compound valsartan amlodipine solid preparation
CA2870675C (en) Solid composition comprising salt of aminocarboxylic acid
CN115317456A (en) Nicorandil tablet composition and preparation method thereof
CN112843010A (en) Sitagliptin pharmaceutical composition and preparation process thereof
CN105193841A (en) Compound reserpine medicine composition for treating hypertension and preparation method of compound reserpine medicine composition
JP2512302B2 (en) Method for producing nicorandil-stabilized preparation
US4716042A (en) Stabilized coated aspirin tablets
CN100377746C (en) Method of stabilizing preparation
CN108721235B (en) Solid pharmaceutical composition containing trimetazidine or salt thereof and preparation method thereof
KR102627892B1 (en) Rapid release drug formulation of anticoagulant and method for manufacturing same
CN85101820A (en) The method for preparing a kind of nifedipine compound formulation
CN105534980B (en) The pharmaceutical composition and its preparation process of Repaglinide Metformin hydrochloride
CN85101689A (en) Nifedipine preparation and preparation method thereof
WO1996003128A1 (en) Preparation of fusidic acid tablets
CN112336711B (en) Glucozine lysine orally disintegrating tablet
CN116803378B (en) Gliclazide sustained-release tablet and preparation method thereof
JPH0215522B2 (en)
RU2320337C1 (en) Method for preparing rifabutin-containing antibacterial composition
CN105106173B (en) Acipimox capsule and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination